HC Wainwright Has Bearish Forecast for REGENXBIO Q3 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at HC Wainwright dropped their Q3 2026 EPS estimates for shares of REGENXBIO in a research note issued on Tuesday, February 10th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($0.61) for the quarter, down from their prior estimate of ($0.22). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($3.63) EPS.

Other research analysts also recently issued reports about the company. Morgan Stanley dropped their price target on REGENXBIO from $25.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday. Royal Bank Of Canada raised their price objective on shares of REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Chardan Capital dropped their price objective on REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. Stifel Nicolaus boosted their target price on REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Barclays assumed coverage on shares of REGENXBIO in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.80.

REGENXBIO Price Performance

RGNX stock opened at $8.35 on Thursday. The stock has a market capitalization of $422.68 million, a price-to-earnings ratio of -2.41 and a beta of 1.05. The company has a 50-day moving average of $13.18 and a two-hundred day moving average of $11.39. REGENXBIO has a 52-week low of $5.03 and a 52-week high of $16.19.

Institutional Trading of REGENXBIO

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State of Alaska Department of Revenue acquired a new position in REGENXBIO during the third quarter worth $25,000. Aquatic Capital Management LLC bought a new position in shares of REGENXBIO in the 3rd quarter valued at about $37,000. Jones Financial Companies Lllp raised its holdings in REGENXBIO by 44.4% during the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares in the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of REGENXBIO by 754.1% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new position in shares of REGENXBIO during the 2nd quarter worth approximately $85,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO News Roundup

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Clear Street argues there’s still large upside to RGNX despite the FDA pushback, offering a bullish take that could attract speculative buyers. Regenxbio stock still has over 300% upside despite FDA pushback on Hunter syndrome drug: Clear Street
• Neutral Sentiment: HC Wainwright kept a “Buy” rating and a $32 price target on RGNX, which may reduce some downside pressure by signaling conviction from at least one equity research shop. MarketBeat REGENXBIO coverage
• Negative Sentiment: The U.S. Food & Drug Administration declined to approve REGENXBIO’s RGX-121 gene therapy for Hunter syndrome — the primary near-term catalyst — which directly undermines the company’s commercialization timeline and revenue prospects. US FDA rejection sends Regenxbio shares sharply lower
• Negative Sentiment: HC Wainwright sharply reduced Q3/Q4 and FY2026 EPS estimates for RGNX (moving quarterly forecasts from about ($0.22) to ($0.61) and cutting FY guidance), signaling weaker near-term financial outlook and increasing uncertainty around cash burn and financing needs. HC Wainwright research note
• Negative Sentiment: Chardan Capital lowered its expectations for RGNX, adding further sell-side skepticism and pressure on the stock’s sentiment. Chardan Capital Has Lowered Expectations for REGENXBIO
• Negative Sentiment: Investor litigation risk emerged — Pomerantz LLP opened an investigation into RGNX investors, which typically raises legal uncertainty and potential costs. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. – RGNX

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.